Browse studies

Find your next paid study

1 recruiting study matching your filters

Phase II Dose Optimization Study of Platinum/Etoposide Plus Ivonescimab (CEI) as First-Line Treatment of Extensive-Stage Small Cell Lung Cancer

Eligible untreated participants with Extensive Stage Small Cell Lung Cancer (ES-SCLC) who are ≥ 18 years of age will be randomized to receive ivonescimab 10 mi…

Extensive Stage Lung Small Cell Cancer

PrECOG, LLC.NCT07057791